INNOVATIVE APPROACHES IN CARDIOVASCULAR DISEASE
SER100 is an opioid-1 (ORL1, nociceptin receptor) partial agonist previously known as ZP120. SER100 was acquired from Zealand Pharma A/S in 2010. The results from previous studies in chronic and acute heart failure indicate that SER100 has a potential to treat isolated systolic hypertension (ISH), and indication which Serodus is pursuing with a Clinical Phase IIa trial. The Phase IIa trial is ongoing.
Patients with ISH are more likely to develop myocardial and vascular remodelling and arteriosclerosis, which predispose them to stroke, renal failure and myocardial infarction. Diabetes, chronic renal failure and obesity are other risk factors in patients with established ISH, and these patients have a significantly higher incidence of congestive heart failure than those with only increased diastolic pressure.
SER150 is a dual acting thromboxane receptor antagonist and thromboxane synthase inhibitor, previously known as EV-077. The product was licensed from the Swiss company Evolva SA in 2013. Early clinical studies indicate an effect on albuminuria in patients with diabetic nephropathy. Serodus is in the planning phase for a clinical phase II study in this patient group.
SER130 is an interleukin-4 (IL-4) partial receptor agonist, which inhibits liberation of TNFα in cells stimulated in an inflammatory cascade. In experimental inflammatory in vivo models SER130 has proven to inhibit inflammation. SER130 is a "First in Class" compound and will shortly enter the preclinical development phase. Acute Myocardial Infarction commonly known as heart attack, results from interruption of blood supply to a part of the heart muscle, causing the heart cells to die. In the first few hours after a heart attack a pronounced inflammation is mobilized in the heart tissue around the area with significant decrease in blood and oxygen supply. This inflammatory process worsens the tissue damage and appears to play a pivota